Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) Sees Significant Growth in Short Interest

Share on StockTwits

Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) was the recipient of a significant growth in short interest in the month of October. As of October 31st, there was short interest totalling 1,220,000 shares, a growth of 85.7% from the September 30th total of 656,900 shares. Based on an average daily trading volume, of 546,900 shares, the short-interest ratio is presently 2.2 days. Approximately 10.5% of the company’s shares are short sold.

Separately, Maxim Group set a $2.00 price target on shares of Navidea Biopharmaceuticals and gave the stock a “buy” rating in a research report on Friday, August 9th.

Shares of NYSEAMERICAN NAVB opened at $0.68 on Thursday. Navidea Biopharmaceuticals has a fifty-two week low of $0.49 and a fifty-two week high of $4.40.

Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.17). The firm had revenue of $0.24 million for the quarter.

Navidea Biopharmaceuticals Company Profile

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment.

Recommended Story: What is a death cross?

Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with's FREE daily email newsletter.